Peritoneal Dialysis Fluid with Complement Inhibitor

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The major concern limiting long-term treatment with peritoneal dialysis (PD) is the loss of peritoneal membrane integrity and function due to repeated and prolonged exposure to dialysis solutions, leading to structural alterations such as fibrosis, angiogenesis, and vasculopathy, which accelerate solute transport and reduce ultrafiltration capacity.

Innovation Solution

A composition for peritoneal dialysis comprising a biologically compatible solvent, an osmotic agent, and a complement inhibitor is used. The osmotic agent can be a soluble carbohydrate or amino acids, and the complement inhibitor can be a protein or peptide that inhibits complement activation or enhances natural complement regulators.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If peritoneal dialysis treatment is repeated and prolonged, then dialysis effectiveness is maintained, but peritoneal membrane integrity and function are lost due to structural alterations

Engineering Contradiction:

Improvedialysis effectivenessVSAvoidperitoneal membrane integrity

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The invention converts the harmful effect of complement activation (which causes membrane damage) into a beneficial outcome by adding complement inhibitors to the dialysis solution. The inhibitors block the harmful complement cascade while allowing the dialysis solution to continue its therapeutic function, thus converting the harmful interaction into a protected state that maintains both treatment effectiveness and membrane integrity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Complement inhibitors act as intermediary substances between the dialysis solution and the peritoneal membrane. These inhibitors (such as eculizumab, ravulizumab, or small molecule complement C3/C5 inhibitors) bind to complement components in the solution, preventing them from activating and damaging the membrane, thus mediating a protective effect while allowing dialysis to proceed

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If peritoneal dialysis is used long-term, then patients avoid haemodialysis limitations, but ultrafiltration capacity is reduced due to membrane structural changes

Engineering Contradiction:

Improvetreatment flexibilityVSAvoidultrafiltration capacity

Core Design Contradiction:

Adaptability or versatilityVSProductivity

Solution Approach 1:

By adding complement inhibitors to the dialysis solution, the invention converts the harmful process of complement-mediated membrane damage into a protected state. This preserves the ultrafiltration capacity that enables treatment flexibility, allowing patients to continue benefiting from home-based dialysis without the membrane dysfunction that would otherwise limit long-term use

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If repeated PD treatments are administered, then continuous toxin removal is achieved, but fibrosis and angiogenesis accelerate membrane deterioration

Engineering Contradiction:

Improvetoxin removal efficiencyVSAvoidmembrane structural alterations

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

Complement inhibitors serve as intermediary agents that intercept the harmful complement activation pathway before it can cause fibrosis and angiogenesis. By binding to complement components in the dialysis solution, these inhibitors prevent the cascade that leads to membrane structural alterations, allowing repeated treatments to continue without accelerating deterioration

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention transforms the harmful effect of repeated complement activation into a beneficial outcome by using complement inhibitors. The inhibitors convert the potentially damaging repeated exposures into protected interactions, maintaining toxin removal efficiency while preventing the accumulation of structural damage that would otherwise occur with repeated treatments

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of this composition reduces or slows the rate of structural and functional alterations in the peritoneal membrane, allowing patients to continue PD treatment for longer periods without compromising membrane integrity.

Implementation Method 1

the composition is used in PD by transferring the composition into the peritoneal cavity of a patient and allowing it to remain there for a sufficient length of time to draw toxins across the peritoneal membrane from the blood of the patient into the composition

Methodology Applied

Scientific EffectOsmosis: Osmosis

Data Source

PatentUS20250170316A1Peritoneal dialysis fluid composition comprising a complement inhibitor

Publication Date: 2025.05.29 INVIZIUS LIMITED

AI summary

A composition for the use in peritoneal dialysis (PD) is hereby provided, the composition comprising a biologically compatible solvent, an osmotic agent and a complement inhibitor. Methods of manufacturing and of use of the composition are also provided.